B3GNT3 and metastatic malignant neoplasm in the lymph nodes: Similarly, in our cohort, low expression of B3GNT3 was associated with several risk factors, including advanced pTNM stage and a higher probability of lymph node metastasis, which contribute to poor prognosis.